Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy
Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Home/Stocks/KARD/Catalyst
Phase 2Data readout

Tonlamarsen

Acute severe hypertension (ASH), post-hospitalization BP management

KARDKardigan™
Expected catalystJune 30, 2027Company guidance: Jun 30, 2027

Catalyst overview

Event details

Drug or asset
Tonlamarsen
Development stage
Phase 2
Event type
Data readout
Indication
Acute severe hypertension (ASH), post-hospitalization BP management

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for Tonlamarsen in Acute severe hypertension (ASH), post-hospitalization BP management. The expected timing is based on the latest available company guidance and may change.

Development notes

KARDINAL-ASH trial. 03/28/26:- Showed significant AGT reduction and clinically meaningful oSBP lowering. 06/11/26:- Trial ongoing; Ph2b topline data in H1 2027. 08/12/26:- KARDINAL-ASH first patient randomized. Ph2 topline data expected in H1 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

More from KARD

Related pipeline programs

Phase 2b

Danicamtiv

Genetic / familial dilated cardiomyopathy (DCM)

View company pipeline
Phase 2b

Ataciguat

Moderate calcific aortic valve stenosis (CAVS)

View company pipeline

Company

Kardigan™

KARD · NasdaqGM
Industry
Biotechnology
Pipeline assets
3
View KARD research

BioPharma Pro

Track every date change

Watchlists, source history and catalyst alerts will be available with Pro.

Start free

Updated Aug 23, 2026. Dates can change; this is not investment advice.

Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy